Who owns KROS?
Institutional ownership of Keros Therapeutics Inc. from Form 13F, Q2 2026
132 institutional managers reported holding Keros Therapeutics Inc. (KROS) in Form 13F filings for Q2 2026, with 19,964,529 shares worth $214M. The largest reported holder was Nantahala Capital Management, LLC. Managers that filed both quarters added a net 1,377,909 shares (+7.4%). 15 opened new positions and 30 sold out.
- Funds holding
- 132
- Value held
- $214M
- New / sold out
- 15 / 30
- Net shares, same filers
- +7.4%
Holdings as of June 30, 2026, the end of Q2 2026. Managers have 45 days after a quarter ends to file Form 13F (by August 14, 2026 for Q2 2026), so positions may have changed since.
Largest holders of KROS
Share of 13F holdings is each fund's shares as a share of the 19,964,529 KROS shares all 13F filers reported, not of shares outstanding.
Biggest buyers in Q2 2026
- Nantahala Capital Management, LLC Added+$15.6M
- AQR Capital Management LLC Added+$6.0M
- Mackenzie Financial Corp Added+$5.1M
- BlackRock, Inc. Added+$4.1M
- ADAR1 Capital Management, LLC Added+$1.6M
- Dimensional Fund Advisors LP Added+$1.5M
- O'Shaughnessy Asset Management, LLC New+$1.4M
- Millennium Management LLC Added+$834K
- Jane Street Group, LLC Added+$758K
- Bridgeway Capital Management, LLC Added+$749K
Biggest sellers in Q2 2026
- Arrowstreet Capital, Limited Partnership Trimmed-$3.8M
- D. E. Shaw & Co., Inc. Trimmed-$2.6M
- Geode Capital Management, LLC Trimmed-$1.8M
- Connor, Clark & Lunn Investment Management Ltd. Trimmed-$1.4M
- Two Sigma Investments, LP Trimmed-$1.3M
- Y-Intercept (Hong Kong) Ltd Trimmed-$1.2M
- Qube Research & Technologies Ltd Trimmed-$1.2M
- Jacobs Levy Equity Management, Inc Trimmed-$1.1M
- Northern Trust Corp Trimmed-$1.1M
- Point72 Asset Management, L.P. Trimmed-$1.1M
The change in shares since the quarter before, adjusted for stock splits and priced at the Q2 2026 value per share. Funds bought $44.0M and sold $29.4M; 45 added and 50 trimmed.
Schedule 13D and 13G filings on KROS
Owners of more than 5% must file within days, so these can be newer than the 13F data.
- 2026-05-15Nantahala Capital Management, LLC SCHEDULE 13G filed by Keros Therapeutics Inc.Schedule 13G
- 2026-04-07BlackRock, Inc. SCHEDULE 13G filed by BlackRock Inc.Schedule 13G
- 2025-10-27D. E. SHAW & CO, L.P. SCHEDULE 13G filed by Keros Therapeutics Inc.Schedule 13G
- 2025-10-23TANG CAPITAL MANAGEMENT LLC SCHEDULE 13G filed by Keros Therapeutics Inc.Schedule 13G
- 2025-05-02JPMORGAN CHASE & CO SCHEDULE 13G filed by Keros Therapeutics Inc.Schedule 13G
- 2025-04-30VANGUARD GROUP INC SCHEDULE 13G filed by Keros Therapeutics Inc.Schedule 13G
- 2025-02-14ALKEON CAPITAL MANAGEMENT LLC SCHEDULE 13G filed by Keros Therapeutics Inc.Schedule 13G
Questions about KROS ownership
- Who owns KROS stock?
- 132 institutional investment managers reported KROS positions in their Form 13F filings for Q2 2026, holding 19,964,529 shares worth $214M in total. Nantahala Capital Management, LLC reported the largest position.
- Are funds buying or selling KROS?
- In Q2 2026, 15 managers opened new KROS positions, 45 added, 50 trimmed and 30 sold out. Managers that filed in both quarters added a net 1,377,909 shares.
- How current is this KROS institutional ownership data?
- It covers holdings as of the end of Q2 2026. Managers have 45 days after the quarter ends to file Form 13F (by August 14, 2026 for Q2 2026), so positions may have changed since.
From the SEC's Form 13F data sets for Q2 2026: every 13F holdings report, matched to KROS by CUSIP. Options are left out. KROS news and filings · KROS insider trades · Top funds